Erez Aminov

Chairman and Chief Executive Officer

Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing Telomir-Zn, a novel oral epigenetic therapy for patients with advanced triple-negative breast cancer (TNBC). Under his leadership, the company advanced Telomir-Zn through preclinical development to FDA IND clearance for a Phase 1/2 clinical trial.

Mr. Aminov leads Telomir’s corporate strategy, financing, business development, intellectual property, and clinical execution. He has successfully structured and executed multiple strategic transactions, including worldwide licensing agreements, acquisitions of global development and commercialization rights, and business development initiatives that have strengthened the Company’s intellectual property portfolio.

Mr. Aminov also serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), where he has overseen the advancement of one clinical-stage development program together with additional preclinical pipeline assets and successfully led the company through its initial public offering.

Before leading public biotechnology companies, Mr. Aminov worked as a consultant, advising on corporate strategy, business development, and strategic transactions within the biotechnology sector.

Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University.